India · Delayed Price · Currency is INR Ajanta Pharma Statistics
Total Valuation
Ajanta Pharma has a market cap or net worth of INR 366.05 billion. The enterprise value is 362.00 billion.
| Market Cap | 366.05B |
| Enterprise Value | 362.00B |
Important Dates
The last earnings date was Tuesday, May 5, 2026.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | Nov 10, 2025 |
Share Statistics
Ajanta Pharma has 124.89 million shares outstanding. The number of shares has decreased by -0.18% in one year.
| Current Share Class | 124.89M |
| Shares Outstanding | 124.89M |
| Shares Change (YoY) | -0.18% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 42.24% |
| Owned by Institutions (%) | 21.56% |
| Float | 41.96M |
Valuation Ratios
The trailing PE ratio is 34.68 and the forward PE ratio is 29.81. Ajanta Pharma's PEG ratio is 1.97.
| PE Ratio | 34.68 |
| Forward PE | 29.81 |
| PS Ratio | 6.71 |
| PB Ratio | 8.09 |
| P/TBV Ratio | 8.16 |
| P/FCF Ratio | 223.16 |
| P/OCF Ratio | 69.17 |
| PEG Ratio | 1.97 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 24.17, with an EV/FCF ratio of 220.69.
| EV / Earnings | 34.28 |
| EV / Sales | 6.64 |
| EV / EBITDA | 24.17 |
| EV / EBIT | 27.33 |
| EV / FCF | 220.69 |
Financial Position
The company has a current ratio of 2.64, with a Debt / Equity ratio of 0.06.
| Current Ratio | 2.64 |
| Quick Ratio | 1.78 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 0.17 |
| Debt / FCF | 1.59 |
| Interest Coverage | 82.23 |
Financial Efficiency
Return on equity (ROE) is 25.39% and return on invested capital (ROIC) is 26.23%.
| Return on Equity (ROE) | 25.39% |
| Return on Assets (ROA) | 14.82% |
| Return on Invested Capital (ROIC) | 26.23% |
| Return on Capital Employed (ROCE) | 27.95% |
| Weighted Average Cost of Capital (WACC) | 5.34% |
| Revenue Per Employee | 5.66M |
| Profits Per Employee | 1.10M |
| Employee Count | 9,628 |
| Asset Turnover | 0.98 |
| Inventory Turnover | 1.29 |
Taxes
In the past 12 months, Ajanta Pharma has paid 3.22 billion in taxes.
| Income Tax | 3.22B |
| Effective Tax Rate | 23.35% |
Stock Price Statistics
The stock price has increased by +16.74% in the last 52 weeks. The beta is 0.20, so Ajanta Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.20 |
| 52-Week Price Change | +16.74% |
| 50-Day Moving Average | 2,930.75 |
| 200-Day Moving Average | 2,725.84 |
| Relative Strength Index (RSI) | 42.54 |
| Average Volume (20 Days) | 168,218 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ajanta Pharma had revenue of INR 54.53 billion and earned 10.56 billion in profits. Earnings per share was 84.51.
| Revenue | 54.53B |
| Gross Profit | 42.69B |
| Operating Income | 13.25B |
| Pretax Income | 13.78B |
| Net Income | 10.56B |
| EBITDA | 14.98B |
| EBIT | 13.25B |
| Earnings Per Share (EPS) | 84.51 |
Balance Sheet
The company has 6.65 billion in cash and 2.60 billion in debt, with a net cash position of 4.04 billion or 32.39 per share.
| Cash & Cash Equivalents | 6.65B |
| Total Debt | 2.60B |
| Net Cash | 4.04B |
| Net Cash Per Share | 32.39 |
| Equity (Book Value) | 45.27B |
| Book Value Per Share | 362.40 |
| Working Capital | 23.20B |
Cash Flow
In the last 12 months, operating cash flow was 5.29 billion and capital expenditures -3.65 billion, giving a free cash flow of 1.64 billion.
| Operating Cash Flow | 5.29B |
| Capital Expenditures | -3.65B |
| Depreciation & Amortization | 1.73B |
| Net Borrowing | 1.98B |
| Free Cash Flow | 1.64B |
| FCF Per Share | 13.13 |
Margins
Gross margin is 78.29%, with operating and profit margins of 24.29% and 19.37%.
| Gross Margin | 78.29% |
| Operating Margin | 24.29% |
| Pretax Margin | 25.26% |
| Profit Margin | 19.37% |
| EBITDA Margin | 27.47% |
| EBIT Margin | 24.29% |
| FCF Margin | 3.01% |
Dividends & Yields
This stock pays an annual dividend of 28.00, which amounts to a dividend yield of 0.96%.
| Dividend Per Share | 28.00 |
| Dividend Yield | 0.96% |
| Dividend Growth (YoY) | -48.15% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 33.12% |
| Buyback Yield | 0.18% |
| Shareholder Yield | 1.13% |
| Earnings Yield | 2.88% |
| FCF Yield | 0.45% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Ajanta Pharma is 3,303.29, which is 12.70% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 3,303.29 |
| Price Target Difference | 12.70% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on June 22, 2022. It was a forward split with a ratio of 1.5.
| Last Split Date | Jun 22, 2022 |
| Split Type | Forward |
| Split Ratio | 1.5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |